1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) - Drugs In Development, 2022, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 21, 130, 152, 12, 15, 233, 55 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 21, 23, 9, 40 and 9 molecules, respectively.
Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler Disease) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Multiple Myeloma (Kahler Disease) - Overview
- Multiple Myeloma (Kahler Disease) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
- Multiple Myeloma (Kahler Disease) - Drug Profiles
- Multiple Myeloma (Kahler Disease) - Dormant Projects
- Multiple Myeloma (Kahler Disease) - Discontinued Products
- Multiple Myeloma (Kahler Disease) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Multiple Myeloma (Kahler Disease), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Multiple Myeloma (Kahler Disease) - Dormant Projects, 2022
- Multiple Myeloma (Kahler Disease) - Discontinued Products, 2022
- Number of Products under Development for Multiple Myeloma (Kahler Disease), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2Seventy Bio Inc
- 4SC AG
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Abbisko Therapeutics Co Ltd
- AbbVie Inc
- Abcuro Inc
- ABL Bio Inc
- Actinium Pharmaceuticals Inc
- Active Biotech AB
- Adicet Bio Inc
- Affimed GmbH
- AKSO Biopharmaceutical Inc
- Alabama Drug Discovery Alliance
- Allogene Therapeutics Inc
- Alloplex Biotherapeutics Inc
- Alphamab Oncology
- Ambrx Biopharma Inc
- Amgen Inc
- Anaveon AG
- Antaimmu BioMed Co Ltd
- Antengene Corp Ltd
- Antion Biosciences SA
- APIM Therapeutics AS
- APO-T BV
- Apollo Therapeutics LLC
- Arcellx Inc
- Arch Oncology Inc
- Arcus Biosciences Inc
- Ariz Precision Medicine Inc
- Arjuna Therapeutics
- Arovella Therapeutics Ltd
- Ascenta Therapeutics Inc
- Ascentage Pharma Group International
- Aslan Pharmaceuticals Ltd
- AstraZeneca Plc
- Asylia Therapeutics Inc
- Auransa Inc
- Aurigene Discovery Technologies Ltd
- Autolus Therapeutics Plc
- Ayala Pharmaceuticals Inc
- Bantam Pharmaceutical LLC
- Bayer AG
- BeiGene Ltd
- Beijing Immunochina Pharmaceuticals Co Ltd
- Beijing Jingda Biotechnology Co Ltd
- Beijing Mabworks Biotech Co Ltd
- Beijing Menlo Biotechnology Co Ltd
- Beijing Sunbio Biotech Co Ltd
- Bellicum Pharmaceuticals Inc
- Betta Pharmaceuticals Co Ltd
- BeyondSpring Inc
- Biocad
- BioCurate Pty Ltd
- Biohaven Pharmaceutical Holding Company Ltd
- Biolexis Therapeutics Inc
- BioLineRx Ltd
- Biomea Fusion Inc
- BioTheryX Inc
- BioVie Inc
- Bivictrix Therapeutics PLC
- Boehringer Ingelheim International GmbH
- Bold Therapeutics Inc
- Bristol-Myers Squibb Co
- C4 Therapeutics Inc
- Calithera Biosciences Inc
- Cantex Pharmaceuticals Inc
- Carbiogene Therapeutics Co Ltd
- Caribou Biosciences Inc
- CARsgen Therapeutics Ltd
- Cartesian Therapeutics Inc
- CASI Pharmaceuticals Inc
- CDR-Life Inc
- Cell Source Inc
- CellCentric Ltd
- Cellectar Biosciences Inc
- Cellectis SA
- Cellenkos Inc
- Cellestia Biotech AG
- Cello Therapeutics Inc
- Cellular Biomedicine Group Inc
- Celularity Inc
- Celyad Oncology SA
- Centrax International Inc
- Ceptur Therapeutics Inc
- Checkpoint Therapeutics Inc
- Cheetah Cell Therapeutics Co Ltd
- Chengdu Zenitar Biomedical Technology Co Ltd
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chimerix Inc
- China Immunotech (Beijing) Biotechnology Co Ltd
- Chinook Therapeutics Inc
- Chong Kun Dang Pharmaceutical Corporation
- Chongqing Precision Biotech Co Ltd
- CiMaas BV
- Cleave Therapeutics Inc
- Compugen Ltd
- Convalife
- Corvus Pharmaceuticals Inc
- CRISPR Therapeutics AG
- CSPC Pharmaceutical Group Ltd
- CStone Pharmaceuticals Co Ltd
- Curocell Inc
- Cyclacel Pharmaceuticals Inc
- Cyteir Therapeutics Inc
- CytoImmune Therapeutics Inc
- Cytovia Holdings Inc
- Daiichi Sankyo Co Ltd
- Dayton Therapeutics AG
- DexTech Medical AB
- Diverse Biotech Inc
- Dragonfly Therapeutics Inc
- Dynamic Cell Therapies Inc
- Eli Lilly and Co
- Elpis Biopharmaceuticals Corp
- EpimAb Biotherapeutics Inc
- Epizyme Inc
- Eternity Bioscience Inc
- eTheRNA Immunotherapies NV
- Eugia Pharma Specialties Ltd
- Eureka Therapeutics Inc
- ExCellThera Inc
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Fera Pharmaceuticals LLC
- Fortis Therapeutics Inc
- Fusion Pharmaceuticals Inc
- Gadeta BV
- Galapagos NV
- Galileo Research srl
- Gamida Cell Ltd
- Genentech USA Inc
- Genmab AS
- Genrix (Shanghai) Biopharmaceutical Co Ltd
- Geron Corp
- Gilead Sciences Inc
- Ginkgo BioWorks Inc
- Gliknik Inc
- GlycoMimetics Inc
- Glycostem Therapeutics BV
- GlyTR Therapeutics Inc
- GP Pharm SA
- GPCR Therapeutics Inc
- Gracell Biotechnologies Inc
- GSK plc
- GT Biopharma Inc
- Guangzhou Bio-gene Technology Co Ltd
- HaemaLogix Pty Ltd
- Hangzhou DAC Biotech Co Ltd
- Hangzhou Sumgen Biotech Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- Harbour BioMed (Guangzhou) Co Ltd
- Harpoon Therapeutics Inc
- Hebei Senlang Biotechnology Co Ltd
- Heidelberg Pharma AG
- Helix BioPharma Corp
- Helocyte Biosciences Inc
- Henan Genuine Biotech Co Ltd
- Hinova Pharmaceuticals Co Ltd
- HitGen Inc
- HK inno.N Corp
- Holy Stone Healthcare Co Ltd
- HRAIN Biotechnology Co Ltd
- Hummingbird Bioscience Pte Ltd
- Hunan Siweikang Therapeutics Ltd
- HuniLife Biotechnology Inc
- Hutchison MediPharma Ltd
- I-Mab
- iCell Gene Therapeutics LLC
- Iceni Pharmaceuticals Ltd
- Ichnos Sciences Inc
- IDAC Theranostics Inc
- IDP Discovery Pharma SL
- IGM Biosciences Inc
- Immix BioPharma Inc
- ImmuneCyte Inc
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- ImmuneTarget Inc
- ImmunityBio Inc
- Immunotech Biopharm Ltd
- Immunwork Inc
- Incyte Corp
- Indapta Therapeutics Inc
- Inflection Biosciences Ltd
- Inmune Bio Inc
- InnoCare Pharma Ltd
- Innovent Biologics Inc
- Intra-Immusg Pvt Ltd
- Inventiva SA
- IO Biotech Inc
- Io Therapeutics Inc
- Ionis Pharmaceuticals Inc
- Ionova Life Science Co Ltd
- Istesso Ltd
- iTeos Therapeutics Inc
- Iterion Therapeutics Inc
- Jiangsu Carephar Pharmaceutical Co Ltd
- Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Kanion Pharmaceutical Co Ltd
- Jiangsu Zhengda Fenghai Pharmaceutical Co Ltd
- Jiangxi Shanxing Biotechnology Co Ltd
- JN Biosciences LLC
- Johnson & Johnson
- JSK Therapeutics Inc
- Jubilant Therapeutics Inc
- Juventas Cell Therapy Ltd
- JW Pharmaceutical Corp
- K36 Therapeutics Inc
- KAHR medical Ltd
- Kangpu Biopharmaceuticals Ltd
- Kartos Therapeutics Inc
- Karyopharm Therapeutics Inc
- Kesios Therapeutics Ltd
- KeyMed Biosciences Inc
- Kirilys Therapeutics Inc
- Kite Pharma Inc
- Klyss Biotech Inc
- Kodikaz Therapeutic Solutions Inc
- Komipharm International Co Ltd
- Kronos Bio Inc
- KYAN Therapeutics Inc
- Kymab Ltd
- Laekna Therapeutics Shanghai Co Ltd
- Lantern Pharma Inc
- LAVA Therapeutics NV
- Leadiant Biosciences Inc
- Legend Biotech Corp
- Les Laboratoires Servier SAS
- Leukogene Therapeutics Inc
- Ligand Pharmaceuticals Inc
- LintonPharm Co Ltd
- Lokon Pharma AB
- Lotus Pharmaceutical Co Ltd
- Loxo Oncology Inc
- Luminary Therapeutics Inc
- Luminus Biosciences Inc
- Luye Pharma Group Ltd
- Mablink Bioscience
- Machavert Pharmaceuticals LLC
- Marker Therapeutics Inc
- Max Biopharma Inc
- MediGene AG
- MedPacto Inc
- Mendus AB
- Merck & Co Inc
- Millennium Pharmaceuticals Inc
- Miltenyi Biomedicine GmbH
- MimiVax LLC
- MiNK Therapeutics Inc
- Modulation Therapeutics Inc
- Molecular Partners AG
- Molecular Templates Inc
- Monte Rosa Therapeutics Inc
- Morphogenesis Inc
- MorphoSys AG
- Multitude therapeutics Inc
- Mustang Bio Inc
- Mycovia Pharmaceuticals Inc
- Nanexa AB
- Nanjing Aimeifei Biomedical Technology Co Ltd
- Nanjing Bioheng Biotech Co Ltd
- Nanjing IASO Biotherapeutics Co Ltd
- Nektar Therapeutics
- Neomics Pharmaceuticals LLC
- Neonc Technologies Inc
- Nerviano Medical Sciences SRL
- Newave Pharmaceutical Inc
- NewBay Medical Technology Co Ltd
- NGM Biopharmaceuticals Inc
- Northlake International LLC
- Novartis AG
- Oncodesign SA
- OncoFusion Therapeutics Inc
- Oncolytics Biotech Inc
- Oncolyze Inc
- OncoMyx Therapeutics Inc
- Onconova Therapeutics Inc
- OncoPep Inc
- Oncopeptides AB
- OncoTartis Inc
- OncoTherapy Science Inc
- One World Cannabis Ltd
- ONK Therapeutics Ltd
- Ono Pharmaceutical Co Ltd
- Onward Therapeutics SA
- Opna Bio SA
- Orgenesis Inc
- ORIC Pharmaceuticals Inc
- Origincell Technology Group Co Ltd
- Otsuka Pharmaceutical Co Ltd
- Oxcia AB
- Paras Biopharmaceuticals Finland Oy
- PentixaPharm GmbH
- PersonGen Anke Cellular Therapeutics Co Ltd
- PersonGen BioTherapeutics (Suzhou) Co Ltd
- Pfizer Inc
- Pharma Mar SA
- Phi Pharma SA
- PI Therapeutics Ltd
- Pimera Inc
- Pinotbio Inc
- Poseida Therapeutics Inc
- Precision Biosciences Inc
- Pregene ShenZhen Biotechnology Co Ltd
- Prelude Therapeutics Inc
- Prescient Therapeutics Ltd
- Promontory Therapeutics Inc
- Protheragen Inc
- Qilu Pharmaceutical Co Ltd
- Quadriga BioSciences Inc
- Qwixel Therapeutics LLC
- Rapa Therapeutics LLC
- RAPT Therapeutics Inc
- RE-Stem Biotech Co Ltd
- Recordati SpA
- Regeneron Pharmaceuticals Inc
- Remd Biotherapeutics Inc
- SA Science Inc
- Salarius Pharmaceuticals Inc
- Sana Biotechnology Inc
- Sanofi
- Seagen Inc
- SELLAS Life Sciences Group Inc
- Senhwa Biosciences Inc
- Shandong New Time Pharmaceutical Co Ltd
- Shanghai Biomed-Union Biotechnology Co Ltd
- Shanghai Bioray Laboratory Inc
- Shanghai GeneChem Co Ltd
- Shanghai Henlius Biotech Inc
- Shanghai HyaMab Biotech Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Keqi Pharmaceutical Technology Co Ltd
- Shanghai Novamab Biopharmaceuticals Co Ltd
- Shanghai Theorion Pharmaceutical Co Ltd
- Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
- Shanghai YaKe Biotechnology Co Ltd
- Shenogen Pharma Group Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Shenzhen Neptunus Institute of Pharmaceutical Technology Co Ltd
- Shenzhen Targetrx Inc
- Shuttle Pharmaceuticals Inc
- Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd
- Sichuan Kelun Pharmaceutical Co Ltd
- SignalRx Pharmaceuticals Inc
- SignPath Pharma Inc
- Sorrento Therapeutics Inc
- Spectrum Pharmaceuticals Inc
- Sphaera Pharma Pte Ltd
- SpringWorks Therapeutics Inc
- Starton Therapeutics Inc
- SteroTherapeutics LLC
- Sumitomo Dainippon Pharma Oncology, Inc
- Sunnycell Therapeutics Ltd
- Sunomix Therapeutics
- Sutro Biopharma Inc
- Suzhou JiSheng Pharmaceutical Co Ltd
- Suzhou Maximum Bio-tech Co Ltd
- Synactix Pharmaceuticals Inc
- SynDevRx Inc
- T-Cure Bioscience Inc
- T-CURX GmbH
- TaiRx Inc
- Takeda Pharmaceutical Co Ltd
- Targazyme Inc
- Targovax ASA
- TC BioPharm Ltd
- Telix Pharmaceuticals Ltd
- Theolytics Ltd
- TheraBioPharma Inc
- Tianweiyuan and Biomedicine Shanghai Co Ltd
- TiCARos Co Ltd
- Tiziana Life Sciences Plc
- Tmunity Therapeutics Inc
- Transgene Biotek Ltd
- Triterpenoid Therapeutics Inc
- Triumvira Immunologics Inc
- TSD Life Sciences
- TTY Biopharm Co Ltd
- Up Therapeutics Inc
- UTC Therapeutics Inc
- VaxCell Biotherapeutics Co Ltd
- Vaxil Bio Therapeutics Ltd
- Verastem Inc
- Vichem Chemie Research Ltd
- Vincerx Pharma Inc
- Virtuoso Therapeutics Inc
- Visterra Inc
- Vycellix Inc
- Vyriad Inc
- Wellington Zhaotai Therapies Ltd
- Wigen Biomedicine Technology (Shanghai) Co Ltd
- WindMIL Therapeutics Inc
- Wuhan Bio-Raid Biotechnology Co Ltd
- Wuhan YZY Biopharma Co Ltd
- XBiotech Inc
- Xbrane Biopharma AB
- XEME BioPharma Inc
- Xencor Inc
- Xi'An Yufan Biotechnology Co Ltd
- Xiangxue Life Sciences
- XNK Therapeutics AB
- Zhengda Tianqing Pharmaceutical Group Co Ltd
- Zovis Pharmaceuticals
